Exelixis

Latest news

• Exelixis Shares Rising on CABOMETYX Revenue (opens in a new tab)

  Yahoo Finance · Sep 30, 2026

• Exelixis stock hits all-time high at 59.73 USD By Investing.com (opens in a new tab)

  Investing.com UK · Sep 30, 2026

• Return on equity % of Exelixis, Inc. – HAN:EX9 (opens in a new tab)

  TradingView · Sep 30, 2026

• How Investors Are Reacting To Exelixis (EXEL) FDA Review Extension (opens in a new tab)

  webull.com · Sep 25, 2026

• Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans? (opens in a new tab)

  Yahoo Finance · Sep 24, 2026

• Exelixis, Inc. (EXEL) Stock Forecasts (opens in a new tab)

  Yahoo! Finance Canada · Sep 24, 2026

• Exelixis (EXEL) Gets FDA Review Extension For Zanzalintinib განაცხად tometastatic Colorectal Cancer (opens in a new tab)

  Yahoo Finance · Sep 21, 2026

• Exelixis Eyes Oncology Deals, Readies Zanzalintinib Launch as Cabozantinib Tops $3B (opens in a new tab)

  Yahoo Finance · Sep 17, 2026

• Can Exelixis (EXEL) Stay Cheap After A 185% Five Year Run? (opens in a new tab)

  Simply Wall Street · Sep 17, 2026

• Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval? (opens in a new tab)

  Yahoo Finance · Sep 16, 2026

• Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle (opens in a new tab)

  Yahoo Finance · Sep 15, 2026

• Analysts Offer Insights on NA Companies: Exelixis (EXEL) and Resolution Minerals Ltd. Sponsored ADR (RML) (opens in a new tab)

  The Globe and Mail · Sep 15, 2026

• Exelixis: The FDA Delay Costs Less Than The Market Thinks (NASDAQ:EXEL) (opens in a new tab)

  Seeking Alpha · Sep 14, 2026

• Exelixis: Why The 3-Month Delay Is More Negative Than It May Seem (Downgrade) (opens in a new tab)

  Seeking Alpha · Sep 14, 2026

• FDA delays review of Exelixis' zanzalintinib by 3 months, no new safety issues found (opens in a new tab)

  Pluang · Sep 14, 2026

• Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises (opens in a new tab)

  Yahoo Finance · Sep 14, 2026

• Exelixis (EXEL) Gets Longer FDA Review As Cancer Pipeline Milestone Advances (opens in a new tab)

  Simply Wall Street · Sep 12, 2026

• FDA extends review of Exelixis drug application for metastatic colorectal cancer (opens in a new tab)

  Investing.com India · Sep 11, 2026

• US FDA extends review of Exelixis’ cancer drug (opens in a new tab)

  WSAU · Sep 11, 2026

• After FDA nod for novel Cabometyx formulation, analysts predict limited threat to Exelixis (opens in a new tab)

  Fierce Pharma · Sep 11, 2026

• Exelixis Says FDA Extended Review Period for Colorectal Cancer Drug (opens in a new tab)

  Yahoo Finance · Sep 11, 2026

• Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months (opens in a new tab)

  Yahoo Finance · Sep 11, 2026

• Exelixis stock falls as FDA extends zanzalintinib review By Investing.com (opens in a new tab)

  Investing.com UK · Sep 11, 2026

• Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In (opens in a new tab)

  Benzinga · Sep 11, 2026

• EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term (opens in a new tab)

  Yahoo Finance · Sep 11, 2026

• FDA delays approval decision for Exelixis' tyrosine kinase inhibitor in colorectal cancer (opens in a new tab)

  Fierce Biotech · Sep 11, 2026

• U.S. FDA extends review of Exelixis' cancer drug (opens in a new tab)

  Yahoo Finance · Sep 11, 2026

• US FDA extends review of Exelixis' cancer drug (opens in a new tab)

  Reuters · Sep 11, 2026

• Adagene Receives Milestone Payment From Exelixis (opens in a new tab)

  Yahoo Finance · Sep 9, 2026

• Exelixis at Wells Fargo conference: zanzalintinib takes center stage (opens in a new tab)

  Investing.com India · Sep 8, 2026